<unk> , sold under the brand name Nubeqa, is an antiandrogen medication which is used in the treatment of non-metastatic castration-resistant prostate cancer in men. It is specifically approved to treat non-metastatic castration-resistant prostate cancer (nmCRPC) in conjunction with surgical or medical castration. The medication is taken by mouth twice per day with food. Side effects of<unk>  added to castration may include fatigue, asthenia, pain in the arms and legs, and rash.<unk>  is a nonsteroidal antiandrogen (NSAA), and acts as a selective antagonist of the androgen receptor (AR). It has been referred to as a second- or third-generation NSAA.<unk>  was patented in 2011 and was approved for medical use in USA in July 2019, in the European Union in March 2020 and in Australia in July 2020.
Darolutamide
Bicalutamide
Acetothiolutamide
Apalutamide
Nilutamide
Topilutamide
Flutamide
Salvestrol